Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Colorcon
AstraZeneca
Fish and Richardson
Deloitte
Julphar
McKesson
Harvard Business School
Healthtrust

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,278,105

« Back to Dashboard

Which drugs does patent 9,278,105 protect, and when does it expire?

Patent 9,278,105 protects MINOCIN and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.
Summary for Patent: 9,278,105
Title:Tetracycline compositions
Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
Inventor(s): Griffith; David C. (San Marcose, CA), Boyer; Serge (San Diego, CA), Dudley; Michael N. (San Diego, CA), Hecker; Scott (Del Mar, CA)
Assignee: Rempex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/654,018
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,278,105

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,278,105

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,084,802 Tetracycline compositions ➤ Sign Up
9,744,179 Tetracycline compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Julphar
Chinese Patent Office
Argus Health
Cantor Fitzgerald
Cerilliant
Chubb
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.